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Purpose: Intensity modulated proton therapy (IMPT) allows for 
the delivery of ionizing radiation over a well-defined range with 
minimal exit dose compared to photons, and may further 
improve dose conformality compared to other proton modalities. 
IMPT is not available for brain cancer treatment in Canada. 
Instead, patients who would likely benefit from proton over 
photon therapy are evaluated on a case-by-case basis for referral 
to US facilities. Improved neurocognitive outcomes would 
certainly constitute a strong argument. As such, tools were 
developed to estimate the intelligence quotient (IQ) and the risk 
of hearing loss post radiotherapy and to compare outcomes of 
proton against photon in pediatric brain tumours on a case-by-
case basis. 
Methods and Materials: Pediatric patients who had received 
radical photon intensity modulated radiation therapy (IMRT) 
were randomly selected from our retrospective database: 10 
cases each of craniopharyngioma, ependymoma and 
medulloblastoma, and 20 cases of glioma. The existing planning 
CT and contoured structures were used to generate IMPT plans 
employing a robust optimization procedure. The RBE-corrected 
dose to brain structures and the cochleas were calculated for 
both IMPT and IMRT. A dose dependent IQ model was applied to 
estimate IQ using a Markov chain Monte Carlo technique. 
Cumulative probability distributions (CDF) were calculated to 
perform a statistical interpretation and to compare proton versus 
photon outcomes. The reported incidence of hearing loss as a 
function of cochlear dose in the literature was used to estimate 
the probability of occurrence. 
Results: The average dose to the brain was less in all IMPT plans 
compared to IMRT: ranging from a 6.7% reduction (p = 0.003) in 
the case of medulloblastoma to 38% (p = 0.007) for 
craniopharyngioma. This dose reduction translated into a gain in 
IQ of 1.9 points on average for protons versus photons for the 
whole cohort at five years post-treatment (p = 0.011). In terms 
of specific diseases, the gains in IQ points were 0.8, 1.6, 2.3, and 
2.7 for medulloblastoma, ependymoma, glioma and 
craniopharyngioma, respectively. When estimating the IQ using 
dose to the temporal lobes, these gains increased to 3.1 to 6.0 
IQ points. Overall, the probability for IQ deficits ≥ 7.5 points was 
estimated to be 32% for IMPT compared to 48% for IMRT, an 
absolute reduction of 16% for the whole cohort (p = 0.014). 
Hearing loss probability was evaluated on a per-ear-basis and was 
found to be systematically less for proton versus photon: 2.9% 
versus 7.2% (p < 10-7). 
Conclusions: IQ predictions post IMPT and IMRT were found to 
be very similar, but a modest gain was systematically observed 
for proton in all patients. Given the uncertainties within the IQ 
model used and our reinterpretation, the predicted gains may be 
underestimated. Additional long-term clinical studies are needed 
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Purpose: Patient outcomes with dose escalation for high-grade 
gliomas have been disappointing because of non-central relapses 
and radionecrosis. Dose-painting can maximize central disease 
control, while minimizing the risk of radionecrosis. This study 
aimed to determine whether dose painting with volumetric 
modulated arc therapy (VMAT) for high-grade gliomas using 3,4-
dihydroxy-6-[18F]fluoro-L-phenylalanine (18F-FDOPA) positron 
emission tomography (PET) could achieve dose-escalated 
coverage of biological target volumes (BTVs) without increasing 
the dose to cranial organs at risk (OARs). 
Methods and Materials: Computed tomography, magnetic 
resonance imaging (MRI) and 18F-FDOPA PET/CT images were 
obtained for post-operative radiation therapy planning of 10 
patients with high-grade glioma. The gross tumour volume (GTV) 
was contoured by a radiation oncologist using gadolinium-
enhanced T1 and T2 FLAIR MRI. The clinical target volume (CTV) 
was defined as a 2 cm expansion of the GTV and surgical cavity. 
The planning target volume (PTV) was defined as a 0.5 cm 
expansion of the CTV. Two VMAT plans (Eclipse version 11.031, 
Varian Medical Systems, Palo Alto, CA) were generated for each 
patient: a conventional VMAT plan without dose escalation with 
a prescribed dose of 60 Gy in 30 fractions in the PTV and a plan 
with dose escalation up to a maximum dose of 80 Gy. The BTVs 
were created by thresholding the 18F-FDOPA uptake on PET/CT 
using a linear quadratic model that assumed tracer uptake was 
linearly related to tumour cell density in each image voxel and 
required the number of surviving tumour cells in each voxel to 
be the same. The treatment planning OARs were: brainstem, 
optics (combined optic nerves and chiasm), anterior chambers, 
and retinas. Dose conformity was quantified using van’t Reit’s 
conformation number. Mean OAR and maximum doses were 
compared using two-sided paired t tests (α = 0.05). 
Results: The mean volume of the PTV receiving 95% of the 
prescribed dose (V95%) was 99.1% with and 99.1% without dose-
painting (p = 0.6). The average PTV conformation number was 
high for plans with (0.92) and without (0.93) dose painting. The 
mean V95% was 98.7% for BTV65, 94.6% for BTV70 and 97.2% for 
BTV75. The patient-averaged mean doses were 64.3 Gy for 
BTV65, 68.5 Gy for BTV70, and 73.9 Gy for BTV75. The patient-
averaged maximum doses to the brainstem (43.6 Gy versus 44.5; 
p = 0.9), optics (25.8 Gy versus 25.9 Gy; p = 0.8), anterior 
chambers (5.8 Gy versus 5.9 Gy; p = 0.2) and retinas (8.7 Gy 
versus 8.6 Gy; p = 0.9) did not differ significantly between the 
types of plans.  
Conclusions: Using commercially available treatment planning 
software, dose painting for high-grade gliomas was planned with 
good BTV coverage and no significant change in the dose 
delivered to OARs. 
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Purpose: Evidence-based guidelines confirm a survival 
advantage of adjuvant radiotherapy (ART) for prostatectomy 
(RP) patients with high-risk pathologic features. Delayed referral 
for salvage radiotherapy is under evaluation as an alternative 
strategy, and current Ontario guidelines recommend radiation 
oncology (RO) referral of high-risk cases for discussion of options. 
We sought to evaluate factors associated with referral and use 
of ART after RP for patients with adverse pathology in a recently 
diagnosed cohort.  
Methods and Materials: This retrospective study used electronic 
treatment records linked to Ontario's population-based cancer 
registry and pathology records. Multivariable regression analysis 
was used to evaluate clinical and health systems factors 
associated with radiation oncology (RO) consultation and ART use 
within six months post-RP. 
Results: From January to November 2012, 2663 prostate cancer 
patients (mean age 61.3, s.d. 6.6 years) received RP in Ontario. 
Following RP, 1130 (42.3%) had at least one high-risk pathologic 
feature as a guideline indication for referral: extracapsular 
extension (ECE, 33.2%), seminal vesicle invasion (SVI, 10.1%), or 
positive margins (20.4%). Of these, 466 (41.2%) were seen by RO 
within six months of RP, of which 52.6% received ART. Of the 885 
patients with adverse pathologic risk factors who did not receive 
ART, 75.0% were never assessed by RO. Multivariate analysis 
confirmed that RO assessment within six months was more 
frequent amongst patients with adverse pathology, including 
